Skip to main content
SpringerLink
Log in

Formoterol/budesonide pressurized metered-dose inhaler: a guide to its use in chronic obstructive pulmonary disease

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The use of a single pressurized metered-dose inhaler (pMDI) containing both formoterol (a long-acting β2-selective adrenoreceptor agonist) and budesonide (an inhaled corticosteroid) is an effective, convenient and well- tolerated option for the treatment of adults with symptoms of moderate to severe chronic obstructive pulmonary disease (COPD) and a history of recurrent COPD exacerbations. Two inhalations of formoterol/budesonide pMDI 6/200 µg twice daily provided rapid and durable improvements in lung function, as well as improvements in COPD control, COPD symptoms and health status outcomes, in clinical trials in patients with moderate to very severe COPD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2014. http://www.goldcopd.org. Accessed 17 Jun 2014.

  2. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3:CD010844.

    PubMed  Google Scholar 

  3. Ehrick JD, Wylie J, Goodey AP, et al. Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: not simple math. Ther Deliv. 2014;5(3):297–317.

    Article  CAS  PubMed  Google Scholar 

  4. Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:CD006826.

    PubMed  Google Scholar 

  5. Eklund A, Tronde A, Johannes-Hellberg I, et al. Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. Biopharm Drug Dispos. 2008;29(7):382–95.

    Article  CAS  PubMed  Google Scholar 

  6. Vannair® 6/100 mcg/inhalation and Vannair® 6/200 mcg/inhalation (formoterol fumarate dihydrate/budenoside): Brazilian prescribing information (in Portuguese). Cotia: Astra-Zeneca, 2014.

  7. Vannair® 100/6 and Vannair® 200/6 metered dose inhaler: New Zealand data sheet. Auckland: AstraZeneca Limited, 2013.

  8. Symbicort® 80/4.5 and 160/4.5 inhalation aerosol: US prescribing information. Wilmington: AstraZeneca LP, 2012.

  9. Tronde A, Gillen M, Borgstrom L, et al. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol. 2008;48(11):1300–8.

    Article  CAS  PubMed  Google Scholar 

  10. Tashkin DP, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000.

    Article  CAS  PubMed  Google Scholar 

  11. Rennard SI, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–65.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Lindberg A, Szalai Z, Pullerits T, et al. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology. 2007;12(5):732–9.

    Article  PubMed  Google Scholar 

  13. Chambers F, Ludzik A. In vitro drug delivery performance of a new budesonide/formoterol pressurized metered-dose inhaler. J Aerosol Med Pulm Drug Deliv. 2009;22(2):113–20.

    Article  CAS  PubMed  Google Scholar 

  14. Solkane® 227 pharma and Solkane® 134a pharma: HFA propellants for medical use. Hannover: Solvay Special Chemicals, 2013.

  15. Heyder J, Gebhart J, Rudolf G, et al. Deposition of particles in the human respiratory tract in the size range 0.005–15 µm. J Aerosol Sci. 1986;17:811–25.

    Article  Google Scholar 

  16. Fernández Tena A, Casan Clarà P. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012;48(7):240–6.

    Article  PubMed  Google Scholar 

  17. Yang XL, Liu Y, Luo HY. Respiratory flow in obstructed airways. J Biomech. 2006;39(15):2743–51.

    Article  CAS  PubMed  Google Scholar 

  18. O’Grady K, Doyle DJ, Irish J, et al. Biophysics of airflow within the airway: a review. J Otolaryngol. 1997;26(2):123–8.

    PubMed  Google Scholar 

  19. Luo HY, Liu Y, Yang XL. Particle deposition in obstructed airways. J Biomech. 2007;40(14):3096–104.

    Article  CAS  PubMed  Google Scholar 

  20. Shah S, White M, Uryniak T, et al. The functionality of a budesonide/formoterol pressurized metered-dose inhaler with an integrated actuation counter. Allergy Asthma Proc. 2010;31(1):40–8.

    CAS  PubMed  Google Scholar 

  21. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25(8):2043–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: E. Obarcanin, Sarajevo, Bosnia and Herzegovina.

Disclosure

The preparation of this review was not supported by any external funding. K. A. Lyseng-Williamson is a salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Formoterol/budesonide pressurized metered-dose inhaler: a guide to its use in chronic obstructive pulmonary disease. Drugs Ther Perspect 30, 269–275 (2014). https://doi.org/10.1007/s40267-014-0142-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-014-0142-4

Keywords

Search

Navigation